The 3 Things That Matter for Eli Lilly Now

Eli Lilly (NYSE: LLY) has been one of the best-performing pharmaceutical leaders in the past five years. Thanks to strong clinical and regulatory progress, as well as robust financial results, the drugmaker has routinely impressed Wall Street.Lilly has experienced a slowdown this year, and its shares have underperformed broader equities. Still, the company could turn things around and return to its market-beating ways, especially if it can execute effectively on several fronts.Let's discuss three critical areas of its business to pay close attention to right now.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool